We are delighted to announce the release of 5 NEW Biosimilar Antibodies! InVivoSIM™ research-grade biosimilar monoclonal antibodies have the same active biological components as the original therapeutic antibodies. They can be used in functional assays, pharmacokinetic assays, ELISA, IHC, WB, FC, and in vivo studies as the standard of care benchmarks in humanized mouse models. Biosimilars make it possible to study the biological effects of a drug without the need to source expensive pharmaceutical-grade therapeutics. To learn more about Biosimilar Antibodies, please click here. 

NEW InVivoSIM™ Biosimilar Antibodies:

• Anti-human C5 (Eculizumab Biosimilar) | Cat#:SIM0011 NEW
• Anti-human IL-6R (Tocilizumab Biosimilar) |Cat#:SIM0014 NEW
• Anti-human IL-17A (Secukinumab Biosimilar)|Cat#:SIM0013 NEW
• Anti-human PD-1 (Pembrolimumab Biosimilar) | Cat#:SIM0010 NEW
• Anti-human VEGFR-2 (Ramucirumab Biosimilar) | Cat#:SIM0012 NEW

*InVivoSIM™ Biosimilar Antibodies are for research use only.  

Click here to Download NEW Brochures.